%	O
%	O
TITLE	O

Impact	O
of	O
antibiotic	O
de	O
-	O
escalation	O
on	O
clinical	O
outcomes	O
in	O
community	B-Pneumococcal_Disease_Type
-	I-Pneumococcal_Disease_Type
acquired	I-Pneumococcal_Disease_Type
pneumococcal	I-Pneumococcal_Disease_Type
pneumonia	I-Pneumococcal_Disease_Type
.	O

%	O
%	O
ABSTRACT	O

Although	O
antibiotic	O
de	O
-	O
escalation	O
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	O
drug	O
effects	O
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community	B-Pneumococcal_Disease_Type
-	I-Pneumococcal_Disease_Type
acquired	I-Pneumococcal_Disease_Type
pneumococcal	I-Pneumococcal_Disease_Type
pneumonia	I-Pneumococcal_Disease_Type
(	O
CAPP	B-Pneumococcal_Disease_Type
)	O
is	O
lacking	O
.	O
We	O
carried	O
out	O
a	O
retrospective	B-Study_Type
analysis	I-Study_Type
of	I-Study_Type
prospectively	I-Study_Type
collected	I-Study_Type
data	I-Study_Type
of	O
a	O
cohort	O
of	O
hospitalized	O
adults	O
with	O
CAPP	B-Pneumococcal_Disease_Type
.	O

Pneumococcal	O
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	O
cultures	O
for	O
Streptococcus	O
pneumoniae	O
obtained	O
from	O
blood	O
,	O
sterile	O
fluids	O
or	O
sputum	O
,	O
and	O
/	O
or	O
a	O
positive	O
urinary	O
antigen	O
test	O
.	O

De	O
-	O
escalation	O
therapy	O
was	O
considered	O
when	O
the	O
initial	O
antibiotic	O
therapy	O
was	O
narrowed	O
to	O
penicillin	O
,	O
amoxicillin	O
or	O
amoxicillin	O
/	O
clavulanate	O
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
.	O

The	O
primary	O
outcomes	O
were	O
30	O
day	O
mortality	O
and	O
length	O
of	O
hospital	O
stay	O
(	O
LOS	O
)	O
.	O

Adjustment	O
for	O
confounders	O
was	O
performed	O
with	O
multivariate	O
and	O
propensity	O
score	O
analyses	O
.	O
Of	O
1410	O
episodes	O
of	O
CAPP	O
,	O
antibiotic	O
de	O
-	O
escalation	O
within	O
the	O
first	O
72	O
h	O
after	O
admission	O
was	O
performed	O
in	O
166	O
cases	O
.	O

After	O
adjustment	O
,	O
antibiotic	O
de	O
-	O
escalation	O
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
mortality	O
(	O
ORâ€Š=â€Š0	O
.	O
83	O
,	O
95	O
%	O
CIâ€Š=â€Š0	O
.	O
24	O
-	O
2	O
.	O
81	O
)	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	O
factor	O
for	O
prolonged	O
LOS	O
(	O
above	O
the	O
median	O
)	O
(	O
ORâ€Š=â€Š0	O
.	O
46	O
,	O
95	O
%	O
CIâ€Š=â€Š0	O
.	O
30	O
-	O
0	O
.	O
70	O
)	O
.	O

Similar	O
results	O
were	O
found	O
in	O
patients	O
classified	O
into	O
high	O
-	O
risk	O
pneumonia	O
severity	O
index	O
classes	O
(	O
IV	O
-	O
V	O
)	O
,	O
those	O
with	O
clinical	O
instability	O
and	O
those	O
with	O
bacteraemia	O
.	O

No	O
significant	O
differences	O
were	O
documented	O
in	O
adverse	O
drug	O
reactions	O
or	O
readmission	O
(	O
<	O
30	O
days	O
)	O
.	O
Antibiotic	O
de	O
-	O
escalation	O
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	O
affect	O
outcomes	O
of	O
patients	O
with	O
CAPP	O
,	O
even	O
those	O
with	O
bacteraemia	O
and	O
severe	O
disease	O
,	O
and	O
those	O
who	O
were	O
clinically	O
unstable	O
.	O

%	O
%	O
METHODS	O

Study	O
design	O

This	O
study	O
was	O
conducted	O
at	O
Hospital	O
Universitari	O
de	O
Bellvitge	O
–	O
IDIBELL	O
,	O
a	O
700	O
bed	O
public	O
hospital	O
in	O
Barcelona	B-Study_Location
,	I-Study_Location
Spain	I-Study_Location
.	O

All	O
adult	O
patients	O
admitted	O
to	O
hospital	O
with	O
CAPP	B-Pneumococcal_Disease_Type
via	O
the	O
emergency	O
department	O
from	O
1	B-Study_Time
February	I-Study_Time
1995	I-Study_Time
to	I-Study_Time
31	I-Study_Time
December	I-Study_Time
2014	I-Study_Time
were	O
prospectively	O
followed	O
-	O
up	O
.	O

Patients	O
who	O
died	O
within	O
the	O
first	O
72	O
h	O
after	O
hospital	O
admission	O
and	O
those	O
who	O
had	O
already	O
received	O
penicillin	O
,	O
amoxicillin	O
or	O
amoxicillin	O
/	O
clavulanate	O
were	O
excluded	O
.	O

At	O
hospital	O
admission	O
,	O
patients	O
underwent	O
a	O
complete	O
clinical	O
history	O
and	O
physical	O
examination	O
.	O

Microbiological	O
studies	O
included	O
two	O
sets	O
of	O
blood	O
cultures	O
and	O
sputum	O
Gram’s	O
stain	O
and	O
culture	O
when	O
available	O
.	O

Urinary	O
antigen	O
detection	O
for	O
S	O
.	O
pneumoniae	O
was	O
performed	O
if	O
indicated	O
by	O
the	O
attending	O
doctor	O
.	O

Patients	O
were	O
stratified	O
into	O
risk	O
classes	O
by	O
the	O
PSI	O
score	O
,	O
as	O
described	O
elsewhere	O
.	O
They	O
were	O
seen	O
daily	O
during	O
their	O
hos	O
-	O
pital	O
stay	O
by	O
one	O
or	O
more	O
of	O
the	O
investigators	O
who	O
recorded	O
clinical	O
,	O
labora	O
-	O
tory	O
and	O
microbiological	O
data	O
in	O
a	O
computer	O
-	O
assisted	O
protocol	O
.	O

Empirical	O
antibiotic	O
treatment	O
was	O
applied	O
according	O
to	O
hospital	O
guidelines	O
,	O
which	O
recommend	O
the	O
administration	O
of	O
a	O
b	O
-	O
lactam	O
agent	O
(	O
ceftriaxone	O
or	O
amoxicillin	O
/	O
clavulanate	O
)	O
with	O
or	O
without	O
a	O
macrolide	O
or	O
a	O
fluoroquinolone	O
.	O

Combination	O
treatment	O
was	O
recommended	O
for	O
patients	O
with	O
clinical	O
suspicion	O
of	O
Legionella	O
or	O
an	O
atypical	O
pathogen	O
,	O
or	O
in	O
the	O
case	O
of	O
severe	O
pneumonia	O
in	O
the	O
absence	O
of	O
a	O
demonstrative	O
sputum	O
Gram’s	O

stain	O
.	O

There	O
was	O
no	O
official	O
hospital	O
policy	O
concerning	O
de	O
-	O
escalation	O
.	O

Definitions	O

CAPP	B-Pneumococcal_Disease_Type
was	O
diagnosed	O
as	O
described	O
elsewhere	O
.	O
Briefly	O
,	O
patients	O
with	O
signs	O
and	O
symptoms	O
of	O
acute	O
-	O
onset	O
respiratory	O
tract	O
infection	O
,	O
new	O
infiltrate	O
on	O
chest	O
X	O
-	O
ray	O
,	O
one	O
or	O
more	O
cultures	O
positive	O
for	O
S	O
.	O
pneumoniae	O
obtained	O
from	O
blood	O
,	O
normally	O
sterile	O
fluids	O
or	O
sputum	O
,	O
and	O
/	O
or	O
a	O
positive	O
urinary	O
antigen	O
test	O
were	O
diagnosed	O
with	O
CAPP	O
.	O

S	O
.	O
pneumoniae	O
was	O
identified	O
using	O
stand	O
-	O
ard	O
microbiology	O
procedures	O
.	O

From	O
2000	O
onwards	O
,	O
urinary	O
antigen	O
detec	O
-	O
tion	O
using	O
a	O
rapid	O
immunochromatographic	O
assay	O
(	O
Binax	O
Now	O
,	O
Binax	O
,	O
Portland	O
,	O
ME	O
,	O
USA	O
)	O
for	O
S	O
.	O
pneumoniae	O
was	O
also	O
available	O
.	O

Clinical	O
stability	O
was	O
defined	O
when	O
the	O
patient	O
met	O
the	O
following	O
objective	O
criteria	O
:	O
ability	O
to	O
maintain	O
oral	O
intake	O
;	O
stable	O
vital	O
signs	O
(	O
considered	O
as	O
temperature	O

,	O
37	O
.	O
88C	O
,	O
respiratory	O
frequency	O
,	O
24	O
breaths	O
/	O
min	O
,	O
systolic	O
blood	O
pressure	O

90	O
mm	O
Hg	O
without	O
vasopressor	O
support	O
)	O
;	O
absence	O
of	O
exacerbated	O
major	O
comorbidities	O
(	O
i	O
.	O
e	O
.	O
heart	O
failure	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
)	O
and	O
/	O
or	O
septic	O
metastases	O
,	O
baseline	O
mental	O
status	O
,	O
and	O
adequate	O
oxygen	O
-	O
ation	O
on	O
room	O
air	O
(	O
PaO2	O
60	O
mm	O
Hg	O
or	O
pulse	O
oximetry	O
90	O
%	O
)	O
.	O

For	O
patients	O
with	O
chronic	O
hypoxemia	O
or	O
receiving	O
chronic	O
oxygen	O
therapy	O
,	O
PaO2	O
or	O
pulse	O
oximetry	O
measurement	O
had	O
to	O
be	O
similar	O
to	O
their	O
baseline	O
values	O
.	O

For	O
the	O
purposes	O
of	O
this	O
study	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
:	O
those	O
with	O
treatment	O
de	O
-	O
escalation	O
and	O
those	O
without	O
treatment	O
de	O
-	O
escalation	O
within	O
72	O
h	O
of	O
hospital	O
admission	O
(	O
henceforth	O
‘de	O
-	O
escalation	O
group’	O
and	O
‘non	O
-	O
de	O
-	O
escalation	O
group’	O
)	O
.	O

De	O
-	O
escalation	O
was	O
considered	O

when	O
the	O
initial	O
antimicrobial	O
spectrum	O
was	O
narrowed	O
to	O
penicillin	O
,	O
amoxi	O
-	O
cillin	O
or	O
amoxicillin	O
/	O
clavulanate	O
within	O
72	O
h	O
of	O
hospital	O
admission	O
,	O
by	O
which	O
time	O
the	O
microbiological	O
test	O
results	O
were	O
usually	O
known	O
.	O

The	O
primary	O
outcome	O
measures	O
were	O
30	O
day	O
mortality	O
and	O
LOS	O
.	O

Thirty	O
day	O
mortality	O
was	O
defined	O
as	O
death	O
due	O
to	O
any	O
cause	O
during	O
≤30	O
days	O
of	O
hospitalization	O
,	O
and	O
LOS	O
was	O
measured	O
in	O
days	O
from	O
the	O
documented	O
time	O
of	O
admission	O
to	O
the	O
documented	O
time	O
of	O
discharge	O
.	O

Prolonged	O
LOS	O
was	O

defined	O
as	O
an	O
LOS	O
greater	O
than	O
the	O
median	O
(	O
in	O
days	O
)	O
.	O

The	O
secondary	O
out	O
-	O
comes	O
were	O
the	O
days	O
of	O
duration	O
of	O
intravenous	O
(	O
iv	O
)	O
antibiotic	O
therapy	O
,	O
the	O
occurrence	O
of	O
adverse	O
events	O
and	O
the	O
subsequent	O
hospital	O
admission	O
.	O

All	O
inpatient	O
antibiotic	O
administration	O
was	O
verified	O
through	O
the	O
paper	O
-	O
based	O
medical	O
administration	O
record	O
.	O

Ethics	O

Written	O
informed	O
consent	O
was	O
considered	O
not	O
necessary	O
for	O
the	O
study	O
,	O
as	O
it	O
was	O
a	O
prospective	O
analysis	O
of	O
our	O
usual	O
everyday	O
work	O
.	O

The	O
data	O
of	O
the	O
patients	O
were	O
anonymized	O
for	O
the	O
purposes	O
of	O
this	O
analysis	O
.	O

Confidential	O
patient	O
information	O
was	O
protected	O
according	O
to	O
national	O
standards	O
.	O

This	O
manuscript	O
has	O
been	O
revised	O
by	O
the	O
Clinical	O
Research	O
Ethics	O
Committee	O
of	O
Bellvitge	O
University	O
Hospital	O
(	O
PR070	O
/	O
16	O
)	O
.	O

Statistical	O
analysis	O

To	O
detect	O
significant	O
differences	O
in	O
clinical	O
,	O
laboratory	O
and	O
outcomes	O
between	O
de	O
-	O
escalated	O
and	O
non	O
-	O
de	O
-	O
escalated	O
groups	O
,	O
we	O
used	O
the	O
x2	O
test	O
or	O
Fisher’s	O
exact	O
test	O
for	O
categorical	O
variables	O
,	O
and	O
Student’s	O
t	O
-	O
test	O
or	O
the	O
Mann–	O
Whitney	O
U	O
-	O
test	O
for	O
continuous	O
variables	O
,	O
when	O
appropriate	O
.	O

The	O
multivariate	O
analysis	O
of	O
factors	O
potentially	O
associated	O
with	O
primary	O
and	O
sec	O
-	O
ondary	O
outcomes	O
included	O
all	O
the	O
statistically	O
significant	O
variables	O
in	O
the	O

univariate	O
analysis	O
and	O
other	O
variables	O
with	O
clinical	O
relevance	O
,	O
including	O
the	O
de	O
-	O
escalated	O
group	O
.	O

Model	O
fit	O
was	O
evaluated	O
with	O
the	O
Hosmer–	O
Lemeshow	O
goodness	O
-	O
of	O
-	O
fit	O
test	O
.	O

We	O
used	O
the	O
stepwise	O
logistic	O
regression	O
model	O
of	O
the	O
SPSS	O
software	O
package	O
(	O
SPSS	O
,	O
version	O
13	O
.	O
5	O
;	O
SPSS	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

An	O
a	O
priori	O
subgroup	O
analysis	O
was	O
performed	O
in	O
patients	O
classified	O
into	O
high	O
-	O
risk	O
groups	O
according	O
to	O
the	O
PSI	O
(	O
classes	O
IV–	O
V	O
)	O
at	O
admission	O
,	O
in	O
those	O
without	O
clinical	O
instability	O
and	O
in	O
those	O
with	O
bacteraemia	O
.	O

Moreover	O
,	O
the	O
probability	O
that	O
a	O
patient	O
has	O
been	O
de	O
-	O
escalated	O
was	O
assessed	O
with	O
multivariate	O
analysis	O
including	O
the	O
factors	O
that	O
might	O
influ	O
-	O
ence	O
the	O
decision	O
to	O
de	O
-	O
escalate	O
antibiotic	O
treatment	O
.	O

This	O
multivariate	O
model	O
was	O
used	O
to	O
create	O
a	O
propensity	O
score	O
for	O
each	O
patient	O
.	O

A	O
multivari	O
-	O
ate	O
analysis	O
for	O
primary	O
and	O
secondary	O
outcomes	O
was	O
performed	O
adjust	O
-	O
ing	O
for	O
the	O
propensity	O
score	O
within	O
the	O
model	O
.	O

Statistical	O
significance	O
was	O
established	O
at	O
a¼	O
0	O
.	O
05	O
.	O

All	O
reported	O
P	O
values	O
are	O
two	O
-	O
tailed	O
.	O

